Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.77 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.77 |
| ▸ | TNF | P01375 | 11/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927794 | 0.91 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4853681 | 0.91 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4914670 | 0.89 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098976 | 0.87 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL537314 | 0.87 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL7746632 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6554664 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL9977590 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL825636 | 0.85 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4479468 | 0.85 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2008-11-13 | — | — | US | claimed |
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE | 2004-08-26 | — | — | US | claimed |
| EP-1246620-A4 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORP (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1246620-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORPORATION (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001045702-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION | 2018-11-08 | — | — | US | disclosed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | NEW YORK UNIVERSITY | 2017-03-30 | — | — | US | disclosed |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-2818164-A1 | Methods of using and compositions comprising PDE4-modulators for treatment, prevention and management of tuberculosis | CELGENE CORPORATION (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20050239867-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | CELGENE CORPORATION | 2005-10-27 | — | — | US | disclosed |
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-06-30 | — | — | US | disclosed |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | CELGENE CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | CELGENE | 2004-08-26 | — | — | US | disclosed |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1246620-A4 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1246620-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-G(A) LEVELS | CELGENE CORPORATION (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001045702-A1 | SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | PDE4A, PDE12, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 8/4885 |
| US-20050239867-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | PDE4A, PDE12, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 8/4885 |
| US-20040091454-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | IL2, IL6, IL1B | PDE4A 295/4885PDE4B 348/4885PDE4C 352/4885 |
| US-20080280967-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | APEH, TNF, ACOX3 | PDE4A 30/4885PDE4B 70/4885PDE4C 53/4885 |
| US-20040167174-A1 | Substituted acylhydroxamic acids and method of reducing TNFalpha levels | TNF, APEH, ACOX3 | PDE4A 14/4885PDE4B 42/4885PDE4C 30/4885 |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
| US-20040175382-A1 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | IL2, IL6, BDNF | PDE4A 1445/4885PDE4B 1668/4885PDE4C 1599/4885 |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.